Ariane Vieira Scarlatelli Macedo

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 770 citations · Full text

Medicine, Cardiology, Oncology +16

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Remo H.M. Furtado et al. · The Lancet · 2021 · 496 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19

Renato D. Lópes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva et al. · JAMA · 2021 · 381 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +6

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer

Ariane Vieira Scarlatelli Macedo, Ludhmila Abrahão Hajjar, Alexander R. Lyon et al. · JACC CardioOncology · 2019 · 163 citations · Full text

Medicine, Oncology, Pharmacology +17

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial

Renato D. Lópes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva et al. · American Heart Journal · 2020 · 144 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14